Associations of Galectin-3 Expression and LGALS-3 (rs4652) Gene Variation with Coronary Artery Disease Risk in Diabetics

  • Samy Hassan 1Medical Biochemistry Department, Faculty of Medicine, University of Zagazig, Zagazig, Egypt
  • Mohamed M M Hassaan
  • Basma A Demasy
  • Norhan Sabbah assistant professor of medical biochemistry ,Zagazig university
DOI: https://doi.org/10.5937/jomb0-30424
Keywords: LGALS-3 (rs4652), Galectin-3 expression, IL-6, T2DM, CAD

Abstract


Background

Galectin‑3 protein that is encoded by lectin galactoside-binding soluble-3 (LGALS-3) gene serves as an important genetic factor in type 2 diabetes mellitus (T2DM) and its cardiovascular obstacles in various populations. We aimed to elicit the pro-inflammatory effect of galectin-3 as determined by interleukin-6 (IL-6) serum levels and to explore the relationship between galectin-3 (LGALS-3 rs4652) gene variation and its expression levels with coronary artery disease (CAD) risk among T2DM Egyptian patients.

Methods:

 112 lean subjects were compared to 100 T2DM without CAD and 84 T2DM with CAD. A tetra-primer amplification refractory mutation system polymerase chain reaction was used to test LGALS-3 (rs4652) and galectin-3 expression was tested with a quantitative real-time polymerase chain reaction. Serum IL-6 was measured using an enzyme-linked immunosorbent assay.

Results:

We found that the prevalence of LGALS-3 (rs4652) AC genotype and galectin-3 gene expression levels in T2DM with CAD were significantly higher than the additional 2 groups and were correlated positively to IL-6 circulating levels also, the C allele carriers (AC+CC) had significantly higher relative Galectin-3 expression levels compared to the A allele carriers (AA).

Conclusion:

 We concluded that galectin-3 expression levels and LGALS-3 (rs4652) AC genotype were coronary artery disease risk factors in type two diabetics among an Egyptian sample.

References

1. Alturfan AA, Basar I, Emekli-Alturfan E, Ayan F, Koldas L, and Emekli N. Galectin-3 and plasma cytokines in patients with acute myocardial infarction. Lab Med 2014;45:336-341.
2. American Diabetes Association. 15. Diabetes Care in the Hospital: Standards of Medical Care in Diabetes-2019. Diabetes Care 2019;42(Suppl 1): S173-S181.
3. Atabaki M, Hashemi M, Daneshvar H, and Alijani E. Lectin, galactoside-binding, soluble, 3 rs4652 A/C gene variation and the risk for rheumatoid arthritis. Biomed Rep 2017;6:251-255.
4. Bobronnikova L. Galectin-3 as a potential biomarker of metabolic disorders and cardiovascular remodeling in patients with hypertension and type 2 diabetes. Vessel Plus 2017;1:61-67.
5. Buccolo G, and David H. Quantitative determination of serum triglycerides by use of enzymes. Clin Chem 1973;19:476-482.
6. De Boer RA, Verweij N, van Veldhuisen DJ, Westra HJ, Bakker SJ, Gansevoort RT, et al. A genome-wide association study of circulating galectin-3. PLoS One 2012;7:e47385.
7. Debrunner M, Schuiki E, Minder E, Straumann E, Naegeli B, Mury R, et al. Proinflammatory cytokines in acute myocardial infarction with and without cardiogenic shock. Clin Res Cardiol 2008;97:298-305.
8. Djordjevic A, Dekleva M, Zivkovic M, Stankovic A, Markovic Nikolic N, Alavantic D, et al. Left ventricular remodeling after the first myocardial infarction in association with LGALS-3 neighbouring variants rs2274273 and rs17128183 and its relative mRNA expression: a prospective study. Mol Biol Rep 2018;45:2227-2236.
9. Djordjevic A, Zivkovic M, Stankovic A, Zivotic I, Koncar I, Davidovic L, et al. Genetic Variants in the Vicinity of LGALS-3 Gene and LGALS-3 mRNA Expression in Advanced Carotid Atherosclerosis: An Exploratory Study. J Clin Lab Anal 2016;30:1150-1157.
10. Dong H, Wang ZH, Zhang N, Liu SD, Zhao JJ, and Liu SY. Serum Galectin-3 level, not Galectin-1, is associated with the clinical feature and outcome in patients with acute ischemic stroke. Oncotarget 2017;8:109752-109761.
11. Fashanu OE, Heckbert SR, Aguilar D, Jensen PN, Ballantyne CM, Basu S, et al. Galectin-3 and Venous Thromboembolism Incidence: the Atherosclerosis Risk in Communities (ARIC) Study. Res Pract Thromb Haemost 2017;1:223-230.
12. Filer A, Bik M, Parsonage GN, Fitton J, Trebilcock E, Howlett K, et al. Galectin 3 induces a distinctive pattern of cytokine and chemokine production in rheumatoid synovial fibroblasts via selective signaling pathways. Arthritis Rheum 2009;60:1604-1614.
13. Frieldewald WT, Levy RI, and Fredrickson DS. Estimation of the concentration of low density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
14. Glovaci D, Fan W, and Wong ND. Epidemiology of Diabetes Mellitus and Cardiovascular Disease. Curr Cardiol Rep 2019;21:21.
15. Hegazi R, El-Gamal M, Abdel-Hady N, and Hamdy O. Epidemiology of and Risk Factors for Type 2 Diabetes in Egypt. Ann Glob Health 2015;81:814-820.
16. Hodeib H, Hagras MM, Abdelhai D, Watany MM, Selim A, Tawfik MA, et al. Galectin-3 as a prognostic biomarker for diabetic nephropathy. Diabetes Metab Syndr Obes 2019;12:325-331.
17. Humphry RW, Cameron A, and Gunn GJ. A practical approach to calculate sample size for herd prevalence surveys. Prev Vet Med 2004;65:173-188.
18. Iacobini C, Amadio L, Oddi G, Ricci C, Barsotti P, Missori S, et al. Role of galectin-3 in diabetic nephropathy. J Am Soc Nephrol 2003;14(8 Suppl 3): S264-S270.
19. Iacobini C, Menini S, Ricci C, Scipioni A, Sansoni V, Cordone S, et al. Accelerated lipid-induced atherogenesis in galectin-3-deficient mice: role of lipoxidation via receptor-mediated mechanisms. Arterioscler Thromb Vasc Biol 2009;29:831-836.
20. Kaplan A, and Glucose K. Clin Chem. The CV Mosby Co., St Louis, Toronto, Princeton, 1984, 436 p.
21. Koshy L, Anju AL, Harikrishnan S, Kutty VR, Jissa VT, Kurikesu I, et al. Evaluating genomic DNA extraction methods from human whole blood using endpoint and real-time PCR assays. Mol Biol Rep 2017;44:97-108.
22. Lind L. Circulating markers of inflammation and atherosclerosis. Atherosclerosis 2003;169:203-214.
23. Livak KJ, and Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C (T)) Method. Methods 2001;25:402-408.
24. MacKinnon AC, Liu X, Hadoke PW, Miller MR, Newby DE, and Sethi T. Inhibition of galectin-3 reduces atherosclerosis in apolipoprotein E-deficient mice. Glycobiology 2013;23:654-663.
25. Madrigal-Matute J, Lindholt JS, Fernandez-Garcia CE, Benito-Martin A, Burillo E, Zalba G, et al. Galectin-3, a biomarker linking oxidative stress and inflammation with the clinical outcomes of patients with atherothrombosis. J Am Heart Assoc 2014;3:e000785.
26. Maiolino G, Rossitto G, Pedon L, Cesari M, Frigo AC, Azzolini M, et al. Galectin-3 predicts long-term cardiovascular death in high-risk patients with coronary artery disease. Arterioscler Thromb Vasc Biol 2015;35:725-732.
27. Mancia G, Fagard R, Narkiewicz K, Redón J, Zanchetti A, Böhm M, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013;31:1281-1357.
28. Menini S, Iacobini C, Blasetti Fantauzzi C, Pesce CM, and Pugliese G. Role of Galectin-3 in Obesity and Impaired Glucose Homeostasis. Oxid Med Cell Longev 2016;2016:9618092.
29. Naito HK. Cholesterol. Clin Chem. The C.V. Mosby Co. St Louis, Toronto, Princeton, 1984, 1194-11206 and 437.
30. Naito HK. High-density lipoprotein (HDL) cholesterol. In: Kaplan A, et al. (eds) Clin Chem. The C.V. Mosby Co. St Louis, Toronto, Princeton, 1984, 1207-1213 and 437.
31. Ozturk D, Celik O, Satilmis S, Aslan S, Erturk M, Cakmak HA, et al. Association between serum galectin-3 levels and coronary atherosclerosis and plaque burden/structure in patients with type 2 diabetes mellitus. Coron Artery Dis 2015;26:396-401.
32. Papaspyridonos M, McNeill E, de Bono JP, Smith A, Burnand KG, Channon KM, et al. Galectin-3 is an amplifier of inflammation in atherosclerotic plaque progression through macrophage activation and monocyte chemoattraction. Arterioscler Thromb Vasc Biol 2008;28:433-440.
33. Pugliese G, Iacobini C, Ricci C, Blasetti Fantauzzi C, and Menini S. Galectin-3 in diabetic patients. Clin Chem Lab Med 2014;52:1413-1423.
34. Qu D, Liu J, Lau CW, and Huang Y. IL-6 in diabetes and cardiovascular complications. Br J Pharmacol 2014;171:3595-3603.
35. Reiner Z. New ESC/EAS Guidelines for the management of dyslipidaemias any controversies behind the consensus? Eur J Cardiovasc Prev Rehabil 2011;18:724-727.
36. Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Res Clin Pract 2019;157:107843.
37. Sciacchitano S, Lavra L, Morgante A, Ulivieri A, Magi F, De Francesco GP, et al. Galectin-3: One Molecule for an Alphabet of Diseases, from A to Z. Int J Mol Sci 2018;19:379.
38. Steffes M, Cleary P, Goldstein D, Little R, Wiedmeyer HM, Rohlfing C, et al. Hemoglobin A1c measurements over nearly two decades: sustaining comparable values throughout the diabetes control and complications trial and the epidemiology of diabetes interventions and complications study. Clin Chem 2005;51:753-758.
39. Tan KCB, Cheung CL, Lee ACH, Lam JKY, Wong Y, and Shiu SWM. Galectin-3 and risk of cardiovascular events and all-cause mortality in type 2 diabetes. Diabetes Metab Res Rev 2019;35:e3093.
40. Tian L, Chen K, Cao J, Han Z, Gao L, Wang Y, et al. Galectin-3-induced oxidized low-density lipoprotein promotes the phenotypic transformation of vascular smooth muscle cells. Mol Med Rep 2015;12:4995-5002.
41. Tuñón J, Blanco-Colio L, Cristóbal C, Tarín N, Higueras J, Huelmos A, et al. Usefulness of a combination of monocyte chemoattractant protein-1, galectin-3, and N-terminal probrain natriuretic peptide to predict cardiovascular events in patients with coronary artery disease. Am J Cardiol 2014;113:434-440.
42. Van Snick J. Interleukin-6: an overview. Annu Rev Immunol 1990;8:253-278.
43. Zhang Y, Wang Y, Zhai M, Gan T, Zhao X, Zhang R, et al. Influence of LGALS3 gene polymorphisms on susceptibility and prognosis of dilated cardiomyopathy in a Northern Han Chinese population. Gene 2018;642:293-298.
44. Zhu W, Sano H, Nagai R, Fukuhara K, Miyazaki A, and Horiuchi S. The role of galectin-3 in endocytosis of advanced glycation end products and modified low density lipoproteins. Biochem Biophys Res Commun 2001;280:1183-1188.
Published
2021/07/08
Issue
Vol. 40 No. 4 (2021): Journal of Medical Biochemistry
Section
Original paper

Copyright (c) 2021 Samy Hassan, Mohamed Hassaan, Basma Demasy, Norhan Sabbah

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.

Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.